

REMARKS

Claims 1-16 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 1-6, drawn to mammalian expression vectors coding for a fusion protein of a glucagons C-terminal side 19-29 and a first method for use for gene therapy;

Group II, claims 8-10, 13 and 14, drawn to a second method of use of mammalian expression vectors coding for a fusion protein of glucagons C-terminal side 19-29, for protein quantification; and

Group III, claims 11 and 12, drawn to a label consisting essentially of a glucagons C-terminal side 19-29 peptide.

For the purpose of examination of the present application, Applicants elect, with traverse, Group I, Claims 1-6. It is submitted that the claims of Group I constitute a common technical feature which links all three groups of claims.



Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

- Attached is a Petition for Extension of Time.
- Attached hereto is the fee transmittal listing the required fees.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 26, 2007

Respectfully submitted,


By 
Gerald M. Murphy, Jr.
Registration No.: 28,977
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road, Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant